The traditional approach to cancer is that the patient must view cancer as the enemy and engage in a war to vanquish that enemy. Ann Wax, RN, argues that this approach is incorrect and invariably leads to pain, self doubt, and depression. Instead, she argues that one must find calm and inner-peace first, in order to promote healing.

The interactions of cells with their surrounding extracellular matrix (ECM) plays a pivotal role in driving normal cell behavior, from development to tissue differentiation and function. At the cellular level, organ homeostasis depends on a productive communication between cells and ECM, which eventually leads to the normal phenotypic repertoire that characterize each cell type in the organism. A failure to establish these normal interactions and to interpret the cues emanating from the ECM is one of the major causes in abnormal development and the pathogenesis of multiple diseases. To recognize and act upon the biophysical signals that are generated by the cross talk between cells and ECM, the cells developed specific receptors, among them a unique set of receptor tyrosine kinases (RTKs), known as the Discoidin Domain Receptors (DDRs). The DDRs are the only RTKs that specifically bind to and are activated by collagen, a major protein component of the ECM. Hence, the DDRs are part of the signaling networks that translate information from the ECM, and thus they are key regulators of cell-matrix interactions. Under physiological conditions, DDRs control cell and tissue homeostasis by acting on collagen sensors; transducing signals that regulate cell polarity, tissue morphogenesis, cell differentiation, and collagen deposition. DDRs play a key role in diseases that are characterized by dysfunction of the stromal component, which lead to abnormal collagen deposition and the resulting fibrotic response that disrupt normal organ function in disease of the cardiovascular system, lungs and kidneys, just to mention a few. In cancer, DDRs are hijacked by tumor and stromal cells to disrupt normal cell-collagen communication and initiate pro-oncogenic programs. Importantly, several cancer types exhibit DDR mutations, which are thought to alter receptor function, and contribute to cancer progression. Therefore, the strong causative association between altered RTK function and disease it is been translated today in the development of specific tyrosine kinase inhibitors targeting DDRs for various disease conditions. In spite of the accumulating evidence highlighting the importance of DDRs in health and diseases, there is still much to learn about these unique RTKs, as of today there is a lack in the medical literature of a book dedicated solely to DDRs. This is the first comprehensive volume dedicated to DDRs, which will fill a gap in the field and serve those interested in the scientific community to learn more about these important receptors in health and disease.

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds-molecules that inhibit the growth of vessels inside a tumor-together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field.

Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics provides a review of the basic anatomy, physiology, biochemistry and pathology of the eye with a focus drug therapy, drug delivery and use of therapeutic medical miniature devices. An understanding of the pharmacological actions of drugs acting on the eye requires the student and health care practitioner to learn additional principles in basic and clinical sciences that are unique to this organ. As a sensory organ, the eye is relatively inaccessible to the systemic circulation due to the blood-vitreous, blood-aqueous and blood-retinal barriers. Consequently, the administration of drugs for therapeutic effects in the eye necessitates an understanding of physico-chemical properties of the molecules and pharmacokinetic principles involved in the access to its site of action via topical, intracameral and intravitreal administration. This book includes information on the general principles of pharmacokinetics and pharmacodynamics of drugs as it pertains to the eye and in combating ocular disorders and diseases. Using a disease-themed approach, the book discusses basic and clinical pharmacological principles involved in the therapy of these diseases including the ocular side effect of systemically-administered drugs, drugs used in ophthalmic surgery and miscellaneous agents, the therapeutic utility of biologics, drug conjugates, combination products, gene and cellular therapy are also covered. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics is useful as a primary and secondary source of reference for up-to-date information about the pharmacological mechanisms of action, pharmacokinetics, side effects, drug-drug interactions and therapeutic indications of drugs for pharmacologists, pharmaceutical scientists, students in the health care disciplines (nursing, pharmacy, optometry, medical), and practitioners in optometry and ophthalmology.

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.

Provides updates on theoretical and practical aspects of different diagnostic and therapeutic procedures. Focuses on issues related to women health and care. Incorporates latest and evidence-based knowledge in all respective fields of obstetrics and gynecology. Gives a broad idea of latest innovations to readers. Contribution from eminent experts. Ready reckoner guide for doing surgical or clinical case in day-to-day practice. This publication will become a valuable aid for the practicing physicians and scientists.

Despite success with treatment when diagnosed early, breast cancer is still one of the most fatal forms of cancer for women. Imaging diagnosis is still one of the most efficient ways to detect early breast changes with mammography among the most used techniques. However, there are other techniques that have emerged as alternatives or even complementary tests in the early detection of breast lesions (e.g., breast thermography and electrical impedance tomography). Artificial intelligence can be used to optimize image diagnosis, increasing the reliability of the reports and supporting professionals who do not have enough knowledge or experience to make good diagnoses. Biomedical Computing for Breast Cancer Detection and Diagnosis is a collection of research that presents a review of the physiology and anatomy of the breast; the dynamics of breast cancer; principles of pattern recognition, artificial neural networks, and computer graphics; and the breast imaging techniques and computational methods to support and optimize the diagnosis. While highlighting topics including mammograms, thermographic imaging, and intelligent systems, this book is ideally designed for medical oncologists, surgeons, biomedical engineers, medical imaging professionals, cancer researchers, academicians, and students in medicine, biomedicine, biomedical engineering, and computer science.

Currently, intensive effort is being directed toward the identification of molecular targets that can provide approaches to the development of novel therapeutic strategies in cancer management. This book focuses on metastasis-associated genes, metastasis promoter and suppressor genes, which relate specifically to behavioral alterations of cancer cells in epithelial mesenchymal transition, cancer stem cell maintenance and propagation, and to the acquisition of invasive and metastasis faculty. The function of these genes has implications for cell cycle regulation and cell proliferation and so constitute an essential element in cancer growth and dissemination. The emphasis in this book is on how appropriate these genes are as molecular targets and how practicable are the constituents of their signal transduction systems as potential candidates and how accessible they are to targeted therapy. Written in a straightforward and clear style with background information supporting the new research, this book will be useful for students and researchers in cancer therapies.
Identifies molecular targets and their accessibility for therapeutic interventionProvides information on biological features of tumor development and dissemination Background information provided for each topic

In this issue of Radiologic Clinics, guest editor Dr. Hillary W. Garner brings her considerable expertise to the topic of Imaging of Bone and Soft Tissue Tumors and Mimickers. Top experts provide timely articles on the imaging findings and other relevant clinical information of frequently encountered benign and malignant tumors of bone and soft tissue, in addition to separate reviews on common and potentially confusing tumor mimics. In addition, orthopaedic oncologists have contributed valuable perspectives on how they incorporate imaging information into their patient care plans. Contains 11 relevant, practice-oriented topics including bone tumors: what the oncology team wants to know; bone tumors: imaging features of common and rare benign entities; bone tumors: common mimickers; soft tissue tumors: what the oncology team wants to know; soft tissue tumors: common mimickers; bone and soft tissue tumors: horizons in radiomics and artificial intelligence; and more. Provides in-depth clinical reviews on imaging of bone and soft tissue tumors and mimickers, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.